Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

12.0K
Multiple sclerosis is an inflammatory demyelinating disease with no cure. Analysis of brain tissue provides important clues to understanding the pathogenesis of the disease. Here we discuss the methodology and downstream analysis of MS brain tissue collected through a unique rapid autopsy program in operation at the Cleveland...
12.0K
The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

58.6K
Precise measurement of neurological and neuropsychological impairment and disability in multiple sclerosis is challenging. We report methodologic details on a new test, the Multiple Sclerosis Performance Test (MSPT). This new approach to the objective of quantification of MS related disability provides a computer-based platform for precise, valid measurement of MS...
58.6K
A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation (tDCS) in Multiple Sclerosis (MS)

18.1K
The goal of this pilot study is to describe a protocol for the remotely-supervised delivery of transcranial direct current stimulation (tDCS) so that the procedure maintains standards of in-clinic practice, including safety, reproducibility, and tolerability. The feasibility of this protocol was tested in participants with multiple sclerosis (MS).
18.1K
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

11.5K
An optimized testing protocol is presented in this paper for the Rotarod performance test, used for measuring progressive neurological disability in TMEV-infected mice.
11.5K
Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis05:44

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis

2.3K
Experimental autoimmune encephalomyelitis is one of the most widely used murine models of multiple sclerosis. In the current protocol, C57BL/6J mice of both sexes are immunized with myelin oligodendrocyte glycoprotein peptide, resulting mainly in ascending paresis of the tail and limbs. Here we discuss the protocol of EAE induction and evaluation.
2.3K
Bioluminescence and Near-infrared Imaging of Optic Neuritis and Brain Inflammation in the EAE Model of Multiple Sclerosis in Mice08:05

Bioluminescence and Near-infrared Imaging of Optic Neuritis and Brain Inflammation in the EAE Model of Multiple Sclerosis in Mice

9.7K
We show a technique for in vivo live bioluminescence and near-infrared imaging of optic neuritis and encephalitis in the experimental autoimmune encephalomyelitis (EAE) model for multiple sclerosis in SJL/J...
9.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient reported outcomes in NMOSD reflect a high disease burden and do not correlate with the EDSS.

Multiple sclerosis and related disorders·2026
Same author

Serum metabolic profile at clinical onset as predictor of multiple sclerosis activity and progression after 5 years.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study.

Journal of neurology·2026
Same author

Best practice recommendations for laboratory analysis and reporting of cerebrospinal fluid oligoclonal banding and associated tests for multiple sclerosis (MS): a consensus report from the harmonized CSF analysis for MS investigation (hCAMI) subcommittee of the Canadian society of clinical chemists (CSCC).

Clinical biochemistry·2026
Same author

Demographic and Clinical Characteristics of Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder in Canadian Adults.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques·2026
Same author

Lipoic Acid for Treatment of Progressive Multiple Sclerosis: A Phase 2 Randomized Clinical Trial.

Neurology·2025

Related Experiment Video

Updated: Jan 19, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.0K

Does Resetting the Immune System Fix Multiple Sclerosis?

Gauruv Bose1, Simon D X Thebault1, Harold L Atkins2

  • 1Department of Medicine-Neurosciences, Division of Neurology, University of Ottawa and the Ottawa Hospital Research Institute, Ottawa Hospital, Ottawa, Canada.

The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques
|September 13, 2019
PubMed
Summary
This summary is machine-generated.

Autologous hematopoietic stem cell transplantation (AHSCT) offers a promising approach to halt inflammatory activity in aggressive multiple sclerosis. This immune reset therapy demonstrates durable responses, potentially altering disease progression in select patients.

Keywords:
HematologyHematopoietic stem cell transplantationMultiple sclerosisNeurology

More Related Videos

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.6K
A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS

Published on: December 26, 2015

18.1K

Related Experiment Videos

Last Updated: Jan 19, 2026

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.0K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.6K
A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS
08:18

A Protocol for the Use of Remotely-Supervised Transcranial Direct Current Stimulation tDCS in Multiple Sclerosis MS

Published on: December 26, 2015

18.1K

Area of Science:

  • Neuroimmunology
  • Stem Cell Transplantation
  • Neurology

Background:

  • Multiple sclerosis (MS) is a leading cause of non-traumatic disability in young adults, impacting up to 100,000 Canadians.
  • Current disease-modifying therapies (DMTs) for MS often fail to prevent ongoing disease activity and disability accrual.
  • Aggressive MS requires advanced therapeutic strategies beyond conventional treatments.

Purpose of the Study:

  • To review the role of immune ablation followed by autologous hematopoietic stem cell transplantation (AHSCT) for aggressive multiple sclerosis.
  • To discuss the efficacy, safety, and future challenges of AHSCT in managing refractory MS.
  • To highlight AHSCT's potential to fundamentally alter the disease trajectory in select patients.

Main Methods:

  • Review of existing literature and clinical trial data on AHSCT for multiple sclerosis.
  • Discussion of immune ablation and hematopoietic stem cell transplantation protocols.
  • Analysis of patient selection criteria, supportive care advancements, and outcome surveillance.

Main Results:

  • AHSCT demonstrates a durable response in halting inflammatory activity in most patients with aggressive MS.
  • The therapy has shown excellent efficacy and safety in recent phase-II trials, with minimized treatment-related mortality.
  • AHSCT can potentially eliminate the need for ongoing disease-modifying therapies (DMTs).

Conclusions:

  • AHSCT represents a significant therapeutic option for select patients with aggressive multiple sclerosis.
  • Ongoing research is needed to compare AHSCT conditioning regimens and identify optimal patient candidates via biomarkers.
  • Long-term outcome surveillance is crucial for understanding the sustained benefits and safety of AHSCT protocols.